RE: The Risks3 Oct 2021 14:49
In terms of this year. I think it is very safe to say that the £100m revenue will come in. Let's exclude the DHSC debacle for now.
2022 forecast should contain £50m from Covid which personally I believe is very conservative. But we'll go with it. Considering Microgen haven't even got out of bed yet so far in 2021 I would expect the bod to have included something for the rapid tests in the £50m workings. Let's assume a measly £10m per annum.
That means Primer Design will contribute about £40m covid revenue in 2022 (that's 40% of 2021). Feels low considering 2022 is only 3 months away and we're seeing an average of 35k cases per day soon to be 6 figures imo. Let's also note that we won't drop to 50% in January. It would phase out over the year so Jan/feb would be same levels as Dec21, Mar would be 90%, Apr 80% and so on. That means ncyt are forecasting next winter to be at around 10-20% of this winter. I don't see it.
Then there's travel, it feels like ncyt are forecasting travel testing to disappear because you either have the requirement or you don't. If it's still applicable to day 2 test then next summer will be a huge market. Millions and millions required and that's just day 2, if its still LFT then Microgen should be all over that making the £10m above look like loose change. So I am assuming ncyt are factoring in worse case that no testing required full stop, other countries no longer bothered because everyone will be vaxxed. Therefore no private travel testing market anymore next summer. That would be great but no way imo.
Then there is the US. They must be setting that up purely for post covid because the £50m covid revenue is more than likely going to be covered off by the UK and Europe alone. Covid is huge at the moment in US and will be working its way up north as the weather gets colder. Ncyt are forecasting nothing in terms of 2022 sales from US. Again, I can't see it. We will be pumping the US hard right now and when we finally get the relevant approvals then happy days.
I can go on but I have proven my point which is that Ncyt haven't got a clue how to forecast this covid situation so they are absolutely low balling it beyond belief. If covid disappears by summer 2022 then yes, £50m will be doable. We would have already by then began the transition into non covid products which would cover the remaining £50m we believe but still to be shown to market. More realistically Covid will still be here next summer and winter and that £100m will forecast will be met by covid alone. Then add on your non covid transition as the R&D team begin to focus on other areas. Then we have the hundreds of RUO assays that we will convert to CE mark. Imo £100m will be toast. All imo but will be very interesting to see how 2022 unfolds.